Compare, Analyse ASTRAZENECA PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
MYLAN
Dec-18
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2783,521-   
Low Rs8831,938-   
Sales per share (Unadj.) Rs228.41,620.4-  
Earnings per share (Unadj.) Rs10.444.0-  
Cash flow per share (Unadj.) Rs16.3347.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.81,752.9-  
Shares outstanding (eoy) m25.00514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 280.8%   
Avg P/E ratio x104.262.0 168.0%  
P/CF ratio (eoy) x66.47.9 845.5%  
Price / Book Value ratio x10.91.6 702.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,404,514 1.9%   
No. of employees `0001.435.0 3.9%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.923,819.4 17.7%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1646.8 29.5%   
INCOME DATA
Net Sales Rs m5,710833,681 0.7%  
Other income Rs m1230-   
Total revenues Rs m5,833833,681 0.7%   
Gross profit Rs m463215,726 0.2%  
Depreciation Rs m147156,098 0.1%   
Interest Rs m040,097 0.0%   
Profit before tax Rs m43819,531 2.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-3,107 -5.8%   
Profit after tax Rs m25922,638 1.1%  
Gross profit margin %8.125.9 31.3%  
Effective tax rate %40.8-15.9 -256.7%   
Net profit margin %4.52.7 167.1%  
BALANCE SHEET DATA
Current assets Rs m3,209465,527 0.7%   
Current liabilities Rs m2,070339,420 0.6%   
Net working cap to sales %20.015.1 132.0%  
Current ratio x1.61.4 113.1%  
Inventory Days Days7284 86.6%  
Debtors Days Days3593 37.4%  
Net fixed assets Rs m790161,720 0.5%   
Share capital Rs m50444 11.3%   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,469901,890 0.3%   
Long term debt Rs m0973,429 0.0%   
Total assets Rs m4,6052,419,220 0.2%  
Interest coverage xNM1.5-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 359.8%   
Return on assets %5.62.6 217.0%  
Return on equity %10.52.5 418.0%  
Return on capital %17.73.2 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88173,239 0.1%  
From Investments Rs m-94-89,545 0.1%  
From Financial Activity Rs mNA-80,705 0.0%  
Net Cashflow Rs m-61,435 -0.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.98 Rs / USD

Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: ALEMBIC  TORRENT PHARMA  PANACEA BIOTECH  WOCKHARDT  CADILA HEALTHCARE  



Today's Market

Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)

The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Intraday Trading for a Living (Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Access Now: Eight Steps to Your Eight Figure Fortune
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

ASTRAZENECA PHARMA SHARE PRICE


Feb 26, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

FEATURED VIDEOS

Nifty is Weak but Smallcaps Can Outperform

Gold 65,000 and Silver 84,000 in 2022

How Long Before a Big Stock Market Crash

I Believe the Investment of the Year Will Be...

More Featured Videos

MARKET STATS